ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Q: What does this research mean for the field?

Combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors generally increases toxicity, necessitating adjustments in treatment protocols. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

E.S.M. van Aken; S.M. O’Cathail; A.K. Gandhi; J. Bussink; L. Castelo-Branco; J.G. Eriksen; G. Argilés; C.T. Hiley; V. Atkinson; J. Kaźmierska; A. Calles; K. Konopa; E. Le Rhun; F. McDonald; G. Mountzios; PM Putora; B. Muoio; U. Ricardi; CB Westphalen; A. Wrona; P. Boot; G. Pentheroudakis; C. Belka; F. Lordick; C.A.M. Marijnen; D. Martins-Branco; D. De Ruysscher; J. Barriuso; B. Devnani; M.C. de Jong; A. Prelaj

doi:10.1016/j.esmoop.2026.106076

Key Points

The aim is to assess the safety of combining radiotherapy with specific targeted agents including EGFR, ALK, and BRAF/MEK inhibitors.
Consensus statements developed by ESMO and ESTRO experts
Evaluation of scenarios for drug interruptions or dosage reductions
Assessment of radiotherapy adaptation strategies.
Increased toxicity is likely when combining treatments
Recommendations for drug interruption or reduction to manage risks
Advocacy for significant adjustments in radiotherapy protocols.

Implication

Consensus statements reveal increased toxicity risk when combining radiotherapy with targeted agents, suggesting safety adaptations.

Abstract

For most scenarios, concurrently combining RT with targeted agents may lead to increased toxicity. Therefore, we recommend a drug interruption, a drug dosage reduction, or a major RT adaptation in various scenarios.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aken et al. (2026) studied this question.

synapsesocial.com/papers/69a528b3f1e85e5c73bf031e https://doi.org/10.1016/j.esmoop.2026.106076

View Full Paper

Ask AI

Bookmark

Share

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Key Points

Implication

Abstract

Discussion

Cite This Study

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading